Effect of Ovarian Stimulation Using Recombinant FSH and GHRH Antagonist in Alternate Days on ICSI Outcomes
Overview
- Phase
- Not Applicable
- Intervention
- Triptorelin
- Conditions
- Infertility
- Sponsor
- Fertility - Assisted Fertilization Center
- Enrollment
- 96
- Locations
- 1
- Primary Endpoint
- cost of treatment
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
The present prospective study was designed to compare the effects of administering a daily dose of gonadotrophin releasing hormone (GnRH) antagonist vs. an alternate-day dosage of GnRH agonist on ovarian response and in vitro fertilization (IVF) outcome in patients stimulated with recombinant follicle-stimulating hormone (FSH) and human chorionic gonadotrophin (hCG) microdose.
Detailed Description
Inclusion criteria were as follows: women of good physical and mental health, under 37 years old, with regular menstrual cycles of 25-35 days, normal basal FSH and luteinizing hormone (LH) levels, body mass index (BMI) less than 30 kg/m2, presence of both ovaries and intact uterus, absence of polycystic ovaries, endometriosis, or gynaecological / medical disorders and a negative result in a screening for sexually transmitted diseases. No patient had received any hormone therapy for at least 60 days preceding the study. Eligible patients who agreed to participate were randomized in two treatment groups. Patients were allocated to a GnRH analogue treatment group according to a computer-generated randomization table.
Investigators
Eligibility Criteria
Inclusion Criteria
- •women of good physical and mental health
- •under 37 years old, with regular menstrual cycles of 25-35 days
- •normal basal FSH and LH levels
- •BMI less than 30 kg/m2
- •presence of both ovaries and intact uterus
- •absence of polycystic ovaries
- •endometriosis, or gynaecological / medical disorders and a negative result in a screening for sexually transmitted diseases
- •all patients signed a written informed consent form
- •no patient had received any hormone therapy for at least 60 days preceding the study.
Exclusion Criteria
- Not provided
Arms & Interventions
GnRH agonist
Administration of GnRH agonist in alternate days, recombinant FSH and hCG microdose for ovarian stimulation.
Intervention: Triptorelin
GnRH antagonist
Daily administration of GnRH antagonist, recombinant FSH and hCG microdose for ovarian stimulation.
Intervention: Cetrorelix
Outcomes
Primary Outcomes
cost of treatment
Time Frame: One month
Secondary Outcomes
- Implantation and pregnancy rates(2 months)